127 related articles for article (PubMed ID: 32543333)
21. Comprehensive analysis of clinical prognostic features and tumor microenvironment landscape of CD11b
Wang Q; Zhang N; Liu L; Ma L; Tan Y; Liu X; Wu J; Chen G; Li X; Liang Y; Zhou F
Cell Oncol (Dordr); 2023 Oct; 46(5):1253-1268. PubMed ID: 37071330
[TBL] [Abstract][Full Text] [Related]
22. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
23. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation.
Krasinskas AM; Wasik MA; Kamoun M; Schretzenmair R; Moore J; Salhany KE
Am J Clin Pathol; 1998 Dec; 110(6):797-805. PubMed ID: 9844593
[TBL] [Abstract][Full Text] [Related]
24. Human intravenous immunoglobulin (hIVIG) inhibits anti-CD32 antibody binding to canine DH82 cells and canine monocytes in vitro.
Sibley TA; Miller MM; Fogle JE
Vet Immunol Immunopathol; 2013 Feb; 151(3-4):229-34. PubMed ID: 23276750
[TBL] [Abstract][Full Text] [Related]
25. Dysregulated Fc receptor function in active rheumatoid arthritis.
Magnusson SE; Wennerberg E; Matt P; Lindqvist U; Kleinau S
Immunol Lett; 2014 Nov; 162(1 Pt A):200-6. PubMed ID: 25194756
[TBL] [Abstract][Full Text] [Related]
26. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Chretien AS; Fauriat C; Orlanducci F; Rey J; Borg GB; Gautherot E; Granjeaud S; Demerle C; Hamel JF; Cerwenka A; von Strandmann EP; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Olive D
Oncotarget; 2017 Jul; 8(30):49548-49563. PubMed ID: 28548938
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotyping is an independent factor for risk stratification in AML.
Repp R; Schaekel U; Helm G; Thiede C; Soucek S; Pascheberg U; Wandt H; Aulitzky W; Bodenstein H; Sonnen R; Link H; Ehninger G; Gramatzki M;
Cytometry B Clin Cytom; 2003 May; 53(1):11-9. PubMed ID: 12717686
[TBL] [Abstract][Full Text] [Related]
28. [Immunophenotyping characteristics of AML and their correlation with the curative effects].
Yang LL; Liu X; Li Q; Zhu XY; Wang XB; Zhu WB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):1-5. PubMed ID: 24598640
[TBL] [Abstract][Full Text] [Related]
29. Decreased expression of FcγRII in active Graves' disease patients.
Lu X; Peng S; Wang X; Shan Z; Teng W
J Clin Lab Anal; 2019 Jul; 33(6):e22904. PubMed ID: 31033004
[TBL] [Abstract][Full Text] [Related]
30. Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis.
Chen X; Cherian S
Clin Lab Med; 2017 Dec; 37(4):753-769. PubMed ID: 29128067
[TBL] [Abstract][Full Text] [Related]
31. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.
Schwartz S; Heinecke A; Zimmermann M; Creutzig U; Schoch C; Harbott J; Fonatsch C; Löffler H; Büchner T; Ludwig WD; Thiel E
Leuk Lymphoma; 1999 Jun; 34(1-2):85-94. PubMed ID: 10350335
[TBL] [Abstract][Full Text] [Related]
32. Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and
Dannheim KC; Pozdnyakova O; Dal Cin P; Weinberg OK
J Clin Pathol; 2018 Dec; 71(12):1051-1059. PubMed ID: 30171088
[TBL] [Abstract][Full Text] [Related]
33. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
Hoffmann MH; Klausen TW; Boegsted M; Larsen SF; Schmitz A; Leinoe EB; Schmiegelow K; Hasle H; Bergmann OJ; Sorensen S; Nyegaard M; Dybkaer K; Johnsen HE
Cytometry B Clin Cytom; 2012 May; 82(3):123-31. PubMed ID: 22328535
[TBL] [Abstract][Full Text] [Related]
35. HLA-G expression is irrelevant to prognosis in patients with acute myeloid leukemia.
Guo QY; Chen BG; Ruan YY; Lin A; Yan WH
Leuk Res; 2011 Oct; 35(10):1350-4. PubMed ID: 21696824
[TBL] [Abstract][Full Text] [Related]
36. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
37. Changed phagocytic activity and pattern of Fcγ and complement receptors on blood monocytes in sarcoidosis.
Dubaniewicz A; Typiak M; Wybieralska M; Szadurska M; Nowakowski S; Staniewicz-Panasik A; Rogoza K; Sternau A; Deeg P; Trzonkowski P
Hum Immunol; 2012 Aug; 73(8):788-94. PubMed ID: 22609476
[TBL] [Abstract][Full Text] [Related]
38. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
40. Fc-gamma receptor expression profile in a North-Indian cohort of pediatric-onset systemic lupus erythematosus: An observational study.
Williams V; Rawat A; Vignesh P; Shandilya JK; Gupta A; Singh S
Int J Rheum Dis; 2019 Mar; 22(3):449-457. PubMed ID: 30399647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
